Fifteen patients with advanced ovarian cancer who progressed or relapsed after initial cisplatinum-based treatment were admitted into a phase II study with oral lonidamine in association with a weekly cisplatin schedule. One complete and four partial clinical responses were observed (5/15:33%). Stable disease and progression were observed in 1 and 9 cases, respectively. The activity demonstrated in refractory or early relapsed patients (14% and 50% objective responses, respectively), together with the good feasibility and tolerability support the clinical use of this regimen, at least as salvage therapy. However, an increased number of patients are needed to better define the role played by lonidamine in the reversal of cisplatin resistance in ovarian cancer and in other tumors.
|Number of pages||4|
|Journal||International Journal of Oncology|
|Publication status||Published - 1994|
- advanced ovarian cancer
- reversal of drug resistance
ASJC Scopus subject areas
- Cancer Research